Toll like receptor modulators
US8853375B2 · kind B2 · utility
13Cited by
3References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 15, 2008 |
| Grant date | Oct 7, 2014 |
| Priority date | — |
| Expiry date | Jul 2, 2031 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to TLR9 antagonist compounds and their therapeutic or prophylactic use. The invention provides novel immune regulatory oligonucleotides and immunomers as antagonist of TLRs and methods of use thereof. These immune regulatory oligonucleotides have unique sequences that suppress, without completely ablating, TLR-mediated signaling in response to a TLR ligand or TLR signaling agonist. The methods may have use in the prevention and treatment of autoimmunity, inflammation, inflammatory bowel disease, lupus, allergy, asthma, infection, sepsis, cancer and immunodeficiency.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.